EMBC · Embecta Corp.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Aug 7, 2026TL;DR. Embecta reported Q3 revenue of $271.7M, down 8.1% YoY but improved sequentially by ~$50M, while reaffirming FY2026 revenue guidance and raising its FY2026 adjusted operating margin guide to 23.5%–24.0% and adjusted EPS guide to $1.80–$1.90 after closing the Owen Mumford deal mid-quarter.
- + Raised FY2026 adjusted EPS guidance to $1.80–$1.90 from $1.55–$1.75.
- + Closed the Owen Mumford acquisition mid-Q3 and is raising M&A contribution guidance.
- + Sequential improvement: revenue +$50M, GAAP operating income +$14M, and adjusted operating income +$21M vs. Q2.
- + International revenue grew 11.5% reported (9.7% adjusted constant currency), driven by Latin America and Asia.
- − Total Q3 revenue fell 8.1% YoY (8.9% adjusted constant currency) to $271.7M.
- − U.S. revenue fell 24.6% YoY in Q3, with greater customer/payer mix impact on net pricing.
- − GAAP net income fell to $21.1M (EPS $0.36) from $45.5M ($0.78) and adjusted EPS fell to $0.56 from $1.12.
- − High-end of FY2026 adjusted organic constant currency revenue growth lowered, driven by U.S. customer/payer mix.
- − Pen needles revenue declined ~18.6% YoY on an adjusted constant currency basis.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA and margin non-GAAP | $247.5M | Nine Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 32.8% | Nine Months Ended June 30, 2026 | — |
| Adjusted gross profit and margin non-GAAP | $453.4M | Nine Months Ended June 30, 2026 | — |
| Adjusted Gross Profit Margin non-GAAP | 60.1% | Nine Months Ended June 30, 2026 | — |
| Adjusted Net Income non-GAAP | $91M | Nine Months Ended June 30, 2026 | — |
| Adjusted net income and adjusted earnings per diluted share non-GAAP | $91M | Nine Months Ended June 30, 2026 | — |
| Adjusted Net Income per Diluted share non-GAAP | $1.53 | Nine Months Ended June 30, 2026 | — |
| Adjusted operating income and margin non-GAAP | $197.3M | Nine Months Ended June 30, 2026 | — |
| Adjusted Operating Income Margin non-GAAP | 26.1% | Nine Months Ended June 30, 2026 | — |
| Adjusted Revenues non-GAAP | $754.7M | Nine Months Ended June 30, 2026 | — |
| Non-GAAP Free Cash Flow non-GAAP | $87.9M | Nine Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EMBC
this stock
Embecta Corp.
|
$334.29M | -52.4% | -3.8% | 4.0 | 9.8% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -30.8% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -15.2% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -9.1% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EMBC | -4.2% | -0.7% | -39.0% | -0.2% | -52.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -4.0% | -0.2% | -51.2% | -1.1% | -65.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.